Chitosan nanofilm and electrospun nanofiber for quick drug release in the treatment of Alzheimer’s disease: In vitro and in vivo evaluation

AnjiReddy, Keshireddy; Karpagam, S.

doi:10.1016/j.ijbiomac.2017.07.021

Cited by 43 publications

(14 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, COS can reduce hippocampal neuronal apoptosis induced by glutamate [ 95 ]. In the vitro drug release profile and in vivo for sampling of blood from donepezil-administered rats, Keshireddy et al [ 96 ] have further reported that rapidly disintegrated donepezil hydrochloride oral thin films were successfully formulated by incorporating microsized CTS thin film, nanosized CTS thin film, and CTS nanofiber in the treatment of AD. In summary, the mechanism by which CTS, COS, and their derivatives treated AD may be through the inhibition of β-secretase activity, anti-neuroinflammation, antioxidant activity, inhibition of acetylcholinesterase activity, and abnormal phosphorylation of tau protein, and adsorption of metal ions is shown by Figure 1 .…”

Section: Biological Activity Of Cts and Cos And Its Derivatives Inmentioning

confidence: 99%

Application of Chitosan, Chitooligosaccharide, and Their Derivatives in the Treatment of Alzheimer’s Disease

Ouyang

Zhao

et al. 2017

Marine Drugs

View full text Add to dashboard Cite

Classic hypotheses of Alzheimer’s disease (AD) include cholinergic neuron death, acetylcholine (ACh) deficiency, metal ion dynamic equilibrium disorder, and deposition of amyloid and tau. Increased evidence suggests neuroinflammation and oxidative stress may cause AD. However, none of these factors induces AD independently, but they are all associated with the formation of Aβ and tau proteins. Current clinical treatments based on ACh deficiency can only temporarily relieve symptoms, accompanied with many side-effects. Hence, searching for natural neuroprotective agents, which can significantly improve the major symptoms and reverse disease progress, have received great attention. Currently, several bioactive marine products have shown neuroprotective activities, immunomodulatory and anti-inflammatory effects with low toxicity and mild side effects in laboratory studies. Recently, chitosan (CTS), chitooligosaccharide (COS) and their derivatives from exoskeletons of crustaceans and cell walls of fungi have shown neuroprotective and antioxidative effects, matrix metalloproteinase inhibition, anti-HIV and anti-inflammatory properties. With regards to the hypotheses of AD, the neuroprotective effect of CTS, COS, and their derivatives on AD-like changes in several models have been reported. CTS and COS exert beneficial effects on cognitive impairments via inhibiting oxidative stress and neuroinflammation. They are also a new type of non-toxic β-secretase and AChE inhibitor. As neuroprotective agents, they could reduce the cell membrane damage caused by copper ions and decrease the content of reactive oxygen species. This review will focus on their anti-neuroinflammation, antioxidants and their inhibition of β-amyloid, acetylcholinesterase and copper ions adsorption. Finally, the limitations and future work will be discussed.

show abstract

Section: Biological Activity Of Cts and Cos And Its Derivatives Inmentioning

confidence: 99%

Application of Chitosan, Chitooligosaccharide, and Their Derivatives in the Treatment of Alzheimer’s Disease

Ouyang

Zhao

et al. 2017

Marine Drugs

View full text Add to dashboard Cite

show abstract

“…Based on the results of the thermal analysis and tensile strength it was noticed that the crosslink-ing with TPP leaded to an increase in the thermal stability and mechanical characteristics and a decrease in swelling degree. The buoyancy test analysis showed also that the NFs mats remain floated onto surface of the dissolution medium more than 48 h, and the mucoadhesive strength analysis emphasize the remarkable bioadhesive strength [44].…”

Section: Cs-nfs As Oral Nanocarriersmentioning

confidence: 90%

“…Ranitidine hydrochloride is an H 2 receptor antagonist highly susceptible to microbial degradation and which has variable absorption in GIT and a half-life of only 2-3 h. These limitations were minimized by the formulation of a floating GRDDS consisted in tripolyphosphate (TPP)-crosslinked NFs mats based on CS and polyethylene oxide [44]. The in vitro drug release studies, showed for the formulated NFs mats a decrease of the initial burst release and a sustained release profile for the ranitidine hydrochloride.…”

Section: Cs-nfs As Oral Nanocarriersmentioning

confidence: 99%

Recent Biomedical Approaches for Chitosan Based Materials as Drug Delivery Nanocarriers

et al. 2021

View full text Add to dashboard Cite

In recent decades, drug delivery systems (DDSs) based on nanotechnology have been attracting substantial interest in the pharmaceutical field, especially those developed based on natural polymers such as chitosan, cellulose, starch, collagen, gelatin, alginate and elastin. Nanomaterials based on chitosan (CS) or chitosan derivatives are broadly investigated as promising nanocarriers due to their biodegradability, good biocompatibility, non-toxicity, low immunogenicity, great versatility and beneficial biological effects. CS, either alone or as composites, are suitable substrates in the fabrication of different types of products like hydrogels, membranes, beads, porous foams, nanoparticles, in-situ gel, microparticles, sponges and nanofibers/scaffolds. Currently, the CS based nanocarriers are intensely studied as controlled and targeted drug release systems for different drugs (anti-inflammatory, antibiotic, anticancer etc.) as well as for proteins/peptides, growth factors, vaccines, small DNA (DNAs) and short interfering RNA (siRNA). This review targets the latest biomedical approaches for CS based nanocarriers such as nanoparticles (NPs) nanofibers (NFs), nanogels (NGs) and chitosan coated liposomes (LPs) and their potential applications for medical and pharmaceutical fields. The advantages and challenges of reviewed CS based nanocarriers for different routes of administration (oral, transmucosal, pulmonary and transdermal) with reference to classical formulations are also emphasized.

show abstract

“…[ 63 ] have reported chitooligosaccharides to protect cultured hippocampal neurons against glutamate-induced neurotoxicity, which suggests that it prevents cultured hippocampal neurons from glutamate-induced cell damage by intrusive with a raise in [Ca 2+ ] and inhibiting caspase-3 activity. In addition to the above studies of chitosan has been used as a vehicle for brain drug delivery because of its good biocompatibility and biodegradability properties [ 66 - 71 ].…”

Section: Role Of Natural or Nutraceuticals Compounds In Alzheimer’s D...mentioning

confidence: 99%

Study of Nutraceuticals and Phytochemicals for the Management of Alzheimer's Disease: A Review

Ahmad

Khalid

Kamal

et al. 2021

View full text Add to dashboard Cite

Background: Alzheimer's disease (AD) affecting several people worldwide and has devastating impacts in society with a limited number of approaches for its pharmacological treatment. The main causes of AD are not clear. However, the formation of senile plaques, neurofibrillary tangles, hyper-phosphorylation of tau protein, and disruption of redox homeostasis is the reason for AD. These causes have a positive correlation with oxidative stress, producing the reactive ions which are responsible for altering the physiological condition of the body. Conclusion: Ongoing research recommended the use of phytochemicals as acetylcholinesterase inhibitors to hinder AD onset and progression. The natural compound structures, including lignans, flavonoids, tannins, polyphenols, triterpenes, sterols, and alkaloids have anti-inflammatory, antioxidant, and anti-amyloidogenic properties. The purpose of this article is to provide a brief introduction to AD along with the use of natural compounds as new therapeutic approaches for its management.

show abstract

Chitosan nanofilm and electrospun nanofiber for quick drug release in the treatment of Alzheimer’s disease: In vitro and in vivo evaluation

Cited by 43 publications

References 36 publications

Application of Chitosan, Chitooligosaccharide, and Their Derivatives in the Treatment of Alzheimer’s Disease

Application of Chitosan, Chitooligosaccharide, and Their Derivatives in the Treatment of Alzheimer’s Disease

Recent Biomedical Approaches for Chitosan Based Materials as Drug Delivery Nanocarriers

Study of Nutraceuticals and Phytochemicals for the Management of Alzheimer's Disease: A Review

Contact Info

Product

Resources

About